Life Sciences
This marks THREAD's third recent acquisition, including the inVibe deal announced early this year and the Modus Outcomes purchase from November.
A new study in The Lancet found that a deep-learning algorithm was able to detect vision-threatening retinopathy with 94.7% accuracy.
The study did not find find a significant difference in depression symptoms between the intervention and control group.
It initially offers medicines and other healthcare products and services from over 500 independent sellers.
A new study published in the Lancet found that patients using VR therapy had a significant reduction in agoraphobic avoidance and distress compared to participants receiving usual care.
The company said it will use the financing to expand in Europe and the U.S., and develop new digital therapeutics with its pharma partners.
The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.
The partnership, which includes Anthem, Biogen, Eli Lilly, Evidation, Janssen and Merck, gives payers guidance for including digital endpoints in reimbursement for new drugs.
The Series C comes about two years after another $150 million raise.
The algorithm analyses EHR data and learns treatment patterns of type 2 diabetes patients.